You Are Reading

Research: Congenital Diaphragmatic Hernia as a Potential Target for Transamniotic Stem Cell Therapy.


Research: Congenital Diaphragmatic Hernia as a Potential Target for Transamniotic Stem Cell Therapy.

J Pediatr Surg. 2019 Nov 9. pii: S0022-3468(19)30768-7. doi: 10.1016/j.jpedsurg.2019.10.033. [Epub ahead of print] https://www.ncbi.nlm.nih.gov/pubmed/31753611

Congenital Diaphragmatic Hernia as a Potential Target for Transamniotic Stem Cell Therapy.

Chalphin AV1Tracy SA1Lazow SP1Kycia I1Zurakowski D1Fauza DO2.

Author information



We sought to determine whether TRASCET could impact congenital diaphragmatic hernia (CDH).


Twelve pregnant dams received Nitrofen on gestational day 9.5 (E9; term = 22 days) to induce fetal CDH. Fetuses were divided into three groups: untreated (n = 31) and two groups receiving volume-matched intraamniotic injections of either saline (n = 37) or a suspension of 2 × 106 cells/mL of amniotic fluid-derived mesenchymal stem cells (afMSCs; n = 65) on E17. Animals were euthanized at term. Expression of fibroblast growth factor-10 (FGF-10), vascular endothelial growth factor-A (VEGF-A), and surfactant protein-C (SPC) was quantified by qRT-PCR. Statistical analysis was by the Mann-Whitney U test with Bonferroni adjusted criterion (p ≤ 0.01).


Among survivors with CDH (n = 27/133), the TRASCET group showed significant downregulation of FGF-10 and VEGF-A gene expressions compared to the untreated (p < 0.001 for both) and saline groups (p = 0.005 and p = 0.004, respectively). SPC expression was higher in the TRASCET group compared to the untreated group (p = 0.01), but not the saline group (p = 0.043). Lung laterality had minimal impact on these comparisons.


Transamniotic stem cell therapy affects select processes of lung development in experimental congenital diaphragmatic hernia. Further scrutiny into this novel therapy as a potential component of the prenatal management of this disease is warranted.


N/A (animal and laboratory study).

Copyright © 2019 Elsevier Inc. All rights reserved.


Amniotic mesenchymal stem cells; Congenital diaphragmatic hernia; Fetal stem cells; Fetal therapy; TRASCET; Transamniotic stem cell therapyPMID: 31753611 DOI: 10.1016/j.jpedsurg.2019.10.033

Leave a Reply

Your email address will not be published. Required fields are marked *

Follow @ Instagram

Follow CDH International